dihexa

Dihexa is a synthetic oligopeptide derived from angiotensin IV that binds **hepatocyte growth factor** (HGF) with high affinity and **potentiates HGF signaling at the c-Met receptor**, producing pro-synaptogenic and procognitive effects in animal models of Alzheimer-like impairment.[1][6] It is orally active, blood–brain barrier permeable, and reported to be highly potent in neurotrophic assays relative to BDNF in preclinical studies.[1][8] Dihexa was invented at Washington State University by Joseph Harding’s group and was later advanced by M3 Biotechnology; a phosphate prodrug, fosgonimeton, entered clinical trials for neurodegenerative diseases.[1]

Other names

N-hexanoic-Tyr-Ile-(6) aminohexanoic amideHexanoyl-Tyr-Ile-Ahx-NH2Hexanoyl-Tyr-Ile-Ahx-NH-2Hexanoyl-Tyr-Ile-Ahx-NH 2L-Isoleucinamide, N-(1-oxohexyl)-L-tyrosyl-N-(6-amino-6-oxohexyl)-